Similar Search Results

Developing novel drugs

Krieger, Joshua L.; Li, Danielle; Papanikolaou, Dimitris - 2018

Persistent link: https://www.econbiz.de/10011875971

Generics and new goods in pharmaceutical price indexes

Griliches, Zvi; Cockburn, Iain - 1993

Persistent link: https://www.econbiz.de/10000857446

The strategic response by pharmaceutical firms to the medicaid most-favored-customer rules

Scott Morton, Fiona - 1996

Persistent link: https://www.econbiz.de/10000601917

The introduction of pharmaceutical product patents in India : "heartless exploitation of the poor and suffering"?

Lanjouw, Jean Olson - 1998

Persistent link: https://www.econbiz.de/10000654419

Perverse incentives in the medicare prescription drug benefit

McAdams, David; Schwarz, Michael - 2006

Persistent link: https://www.econbiz.de/10003287666

Insurer bargaining and negotiated drug prices in medicare Part D

Lakdawalla, Darius; Yin, Wesley - 2009

Persistent link: https://www.econbiz.de/10003885817

Is the Food and Drug Administration safe and effective?

Philipson, Tomas J.; Sun, Eric - 2007

Persistent link: https://www.econbiz.de/10003588021

European pharmaceutical price regulation, firm profitability, and R&D spending

Golec, Joseph; Vernon, John A. - 2006

Persistent link: https://www.econbiz.de/10003392874

The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts

Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - 2011

"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of...

Persistent link: https://www.econbiz.de/10009374023

Assets with "warts" : how reliable is the market for technology?

Palermo, Vincenzo; Higgins, Matthew J.; Ceccagnoli, Marco - 2015

Persistent link: https://www.econbiz.de/10010530696

1
2
3
4
5
6
7
8
9
10
Next
Last